FFC claims Allergan’s complaint violates anti-SLAPP laws
17-08-2015
360b / Shutterstock.com
Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital (FFC) to invalidate a patent covering its Combigan (brimonidine and timolol) drug after the Patent Trial and Appeal Board (PTAB) opted not to institute an inter partes review (IPR).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Ferrum Ferro Capital; Allergan; PTAB; IPR; USPTO; Combigan; glaucoma
